Refugees, internally displaced persons and migrants were exposed to significantly higher health risks during the Covid-19 pandemic than other population groups. A new study shows a 84 per cent higher risk of infection and a 46 per cent higher mortality rate among migrants compared to the general population.
Adagrasib Wins Accelerated Approval for KRAS-Mutant Colorectal Cancer
The FDA granted accelerated approval to adagrasib (Krazati) for KRAS G12C-mutated colorectal cancer (CRC), which accounts for 3-5% of CRCs. The approval stipulates use of
June 22, 2024